The FDA has approved a human clinical study of STAAR Surgical’s EVO/EVO+ Visian ICL for myopia and the EVO/EVO+ Visian toric ICL for myopia with astigmatism, the company announced in a press release.
Study design modifications, recommended by the FDA in a letter dated Aug. 23, will be incorporated into the investigational plan in a revised submission. The current study plan includes 300 subjects with a primary endpoint at 6 months’ follow-up, the release said.
“STAAR looks forward to working with FDA to incorporate the recommended protocol modifications in order (Read more...)
Uncategorized